Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vancomycin

vancomycin

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of vancomycin

62 trials tracked of vancomycin: 35 in phase 3 or 4 and 14 with published results. The most-cited published study has 106 citations.

62Trials tracked
35Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 13 Phase 3 22 Phase 2 15 Phase 1 3 Other / NA 9
  1. Phase 3 Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed · 106 cited
  2. Phase 3 Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed · 104 cited
  3. Phase 3 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) Completed · 72 cited
  4. Phase 3 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) Completed · 71 cited
  5. Phase 3 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea Completed · 66 cited
  6. Phase 3 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea Completed · 66 cited
Show 44 more trials
  1. Phase 3 Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 Completed · 49 cited
  2. Phase 3 Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 Completed · 38 cited
  3. Phase 3 Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Completed · 34 cited
  4. Phase 4 Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin Completed · 32 cited
  5. Phase 3 Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement Completed · 32 cited
  6. Phase 4 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections Completed · 16 cited
  7. Phase 4 Impact of Oral Antibiotic Treatment on C. Difficile Completed · 15 cited
  8. Phase 3 Topical Vancomycin for Neurosurgery Wound Prophylaxis Completed · 9 cited
  9. Phase 4 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL]) Completed
  10. Phase 4 Preoperative Antibiotics for Carpal Tunnel Release Surgery Completed
  11. Phase 4 Responses to Rabies Vaccine in Adults With or Without Antibiotics Completed
  12. Phase 4 Screening to Prophylax Against Clostridium Difficile Infection - Completed
  13. Phase 4 Acute Application of Antibiotic Powder in Open Fracture Wounds Completed
  14. Phase 4 Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA Completed
  15. Phase 4 Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) Completed
  16. Phase 4 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections Completed
  17. Phase 4 Effect of Probiotic Supplementation on Endothelial Function Completed
  18. Phase 4 Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) Completed
  19. Phase 3 Regional Prophylactic Vancomycin in Revision Total Knee Replacement Completed
  20. Phase 3 A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed
  21. Phase 3 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Completed
  22. Phase 3 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed
  23. Phase 3 Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) Completed
  24. Phase 3 PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed
  25. Phase 3 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus Completed
  26. Phase 3 China Registration Study in Patients With Skin Infections Completed
  27. Phase 3 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed
  28. Phase 3 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus Completed
  29. Phase 3 Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections Completed
  30. Phase 2 Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans Completed
  31. Phase 2 Topical Antibiotics in Chronic Rhinosinusitis Completed
  32. Phase 2 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection Completed
  33. Phase 2 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome Completed
  34. Phase 2 A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections Completed
  35. Phase 2 Study of CB-183,315 in Participants With Clostridium Difficile Infection Completed
  36. Phase 2 Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Completed
  37. Phase 2 DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Completed
  38. Phase 2 Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Completed
  39. Phase 2 Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease Completed
  40. Phase 2 PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Completed
  41. Phase 2 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection Completed
  42. Phase 2 Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci Completed
  43. Phase 2 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection Completed
  44. Phase 2 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease Completed

Showing the 50 most-cited and recently-updated of 62 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Fidaxomicin and vancomycin pulse and taper regimens show potential for reducing Clostridioides difficile recurrence
Infectious Disease Meta-analysis
Fidaxomicin and vancomycin pulse and taper regimens show potential for reducing Clostridioides difficile recurrence Fidaxomicin and Vancomycin Pulse Regimens May Reduce Infection Recurrence
Researchers evaluated various treatment regimens, including fidaxomicin and vancomycin pulse and taper strategies, for managing Clostridioid…
New analysis suggests that specific dosing schedules for fidaxomicin and vancomycin may be more effective at preventing recurring C. diffici…
medRxiv Jul 18, 2026
Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases
Infectious Disease Meta-analysis
Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases Vancomycin Powder May Reduce Infections After High Risk Fractures
This meta-analysis of 3185 patients found that intrawound vancomycin powder significantly reduced postoperative infection rates (OR 0.59; 95…
A review of data suggests that using vancomycin powder in wounds may lower infection rates for patients with serious bone fractures.
Jun 11, 2026
Model-informed precision dosing improves vancomycin target attainment in critically ill children compared to standard therapeutic drug monitoring
Infectious Disease RCT
Model-informed precision dosing improves vancomycin target attainment in critically ill children compared to standard therapeutic drug monitoring New dosing model helps severely ill children hit drug targets faster
In critically ill children, model-informed precision dosing significantly improved vancomycin target attainment versus standard monitoring. …
A new dosing method helped more critically ill children reach the right drug levels in their blood within two days of starting treatment for…
Jun 1, 2026
Meta-analysis links vincristine and other drugs to higher cisplatin hearing loss risk in pediatric cancer
ENT (Otolaryngology) Meta-analysis
Meta-analysis links vincristine and other drugs to higher cisplatin hearing loss risk in pediatric cancer Hidden Danger in Kids' Cancer Treatment Raises Hearing Loss Risk
This meta-analysis of observational studies synthesized evidence on concomitant medications and cisplatin-induced hearing loss in pediatric …
• Four common drugs nearly quadruple hearing damage during chemo • Helps oncologists protect children from silent treatment side effects • D…
Frontiers May 14, 2026
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Infectious Disease RCT
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
This randomized clinical trial evaluated adults with operatively treated periarticular tibial fractures at elevated infection risk. Among 16…
A major trial found that adding a second antibiotic powder directly into bone fractures during surgery failed to lower infection rates compa…
JAMA May 12, 2026
Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemia
Infectious Disease RCT
Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemia Positive lab interactions linked to lower early death in MRSA infection treatment
This post hoc analysis of a multicentre randomized trial included 150 adults with MRSA bacteraemia.
When lab tests showed bacteria died better with combined drugs, patients had lower early death rates. This finding suggests smarter drug pai…
May 1, 2026
CRS3123 shows efficacy in phase 2 trial for Clostridioides difficile infection
Infectious Disease RCT
CRS3123 shows efficacy in phase 2 trial for Clostridioides difficile infection Early trial shows CRS3123 matches vancomycin for treating C. diff infection
This phase 2 randomized trial compared CRS3123 with vancomycin in 43 adults with CDI.
A small Phase 2 trial found CRS3123 worked as well as vancomycin for curing C. diff infection in adults with their first episode or recurren…
May 1, 2026
Meta-analysis shows pharmacist interventions improve vancomycin TDM outcomes and reduce kidney injury risk
Drug Pipeline Meta-analysis
Meta-analysis shows pharmacist interventions improve vancomycin TDM outcomes and reduce kidney injury risk Pharmacist oversight improves vancomycin safety and success rates in patients
This meta-analysis evaluated pharmacist interventions versus non-pharmacist interventions in patients treated with vancomycin under therapeu…
A large review shows pharmacist involvement lowers kidney injury risk and improves blood levels for patients taking vancomycin.
Frontiers Apr 29, 2026
Electronic health record study links prior antimicrobial resistance to bacteraemia in cancer patients
Infectious Disease
Electronic health record study links prior antimicrobial resistance to bacteraemia in cancer patients Prior Antibiotic Resistance Linked to Higher Bacteraemia Risk in Cancer Patients
This electronic health record study analyzed 2752 adults with cancer diagnostic codes in Oxfordshire, UK, between 2015 and 2025.
Past antibiotic resistance in cancer patients strongly predicts future bloodstream infections, with specific cancer types increasing odds of…
medRxiv Apr 26, 2026
FMT shifts bile acids faster than vancomycin in recurrent C. difficile infection subgroup
Gastroenterology RCT
FMT shifts bile acids faster than vancomycin in recurrent C. difficile infection subgroup Study looks at bile acids and recurrent C. diff treatments
This randomized controlled trial subgroup analyzed patients with recurrent Clostridioides difficile infection.
Treating recurrent C. diff infection with FMT shifts bile acids faster than vancomycin, restoring a healthy pattern linked to the presence o…
Apr 19, 2026
Vancomycin AUC24 Monitoring Correlates With Trough Levels in Pediatric MRSA Inpatients: A Prospective Multicenter Study
Drug Pipeline Cohort
Vancomycin AUC24 Monitoring Correlates With Trough Levels in Pediatric MRSA Inpatients: A Prospective Multicenter Study Better Vancomycin Dosing Could Protect Children’s Kidneys
This prospective multicenter cohort study included 70 pediatric inpatients with methicillin-resistant Staphylococcus aureus (MRSA).
A new way to measure antibiotic levels in children may prevent kidney damage while fighting infection.
Frontiers Apr 19, 2026
Narrative review suggests combination regimens over vancomycin monotherapy for Elizabethkingia meningoseptica infections
Infectious Disease Sys. Review
Narrative review suggests combination regimens over vancomycin monotherapy for Elizabethkingia meningoseptica infections Is vancomycin alone safe for a rare infection that might actually need a stronger team approach?
This narrative review addresses Elizabethkingia meningoseptica infections, noting that frequent misidentification between E.
Doctors should combine vancomycin with other antibiotics instead of using it alone to treat rare Elizabethkingia infections, because relying…
Frontiers Apr 16, 2026

All vancomycin Articles